The patent expiry of apalutamide represents a significant shift in the market. With increased availability and potentially lower prices, this can be positive news for patients and healthcare systems. However, ensuring quality and maintaining a stable supply chain remain important considerations. As the market evolves, staying informed about developments in generic apalutamide API production and pricing will be crucial for all stakeholders involved. https://www.qingmupharm.com/pr....oducts/human-apis/ap